Thermo Fisher Scientific Inc NYSE:TMO Price, Chart, News & Insight

Thermo Fisher Completes $1.08 Billion Sale of Microbiology Business to Astorg

Thermo Fisher Scientific (NYSE: TMO) has completed the sale of its microbiology business to private equity firm Astorg for approximately $1.075 billion.

The consideration consists primarily of cash along with a $50 million seller note. The divested business generated $645 million in revenue in 2025 and previously operated within Thermo Fisher’s Specialty Diagnostics segment.

The microbiology unit provides antimicrobial susceptibility testing and culture media solutions used in clinical, pharmaceutical and food-safety testing.

The transaction represents a portfolio optimization move for Thermo Fisher, allowing the company to monetize a non-core diagnostics operation while concentrating resources on its broader life sciences, analytical technologies, laboratory products and pharmaceutical services businesses.

With more than $45 billion in annual revenue, the divested operation represents a relatively small portion of Thermo Fisher’s overall business. The $1.075 billion transaction values the microbiology unit at approximately 1.7 times its 2025 revenue.

💬

WS Investor 08-12-26

Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for approximately $1.075 billion, including cash and a $50 million seller note.

The divested unit, which provides antimicrobial testing and culture media solutions for clinical, pharmaceutical, and food safety applications, generated $645 million in revenue in 2025 and is part of Thermo Fisher’s Specialty Diagnostics segment.

The company said the transaction reflects active portfolio management and will provide additional capital to invest in higher-growth areas and enhance shareholder value. The deal is expected to close in the second half of 2026, subject to regulatory approvals and customary conditions.

Thermo Fisher noted the sale will have a modest negative impact on adjusted earnings per share in the first full year after closing.

Business Wire

💬

The Investor 04-27-26

Thermo Fisher Scientific reported first-quarter 2026 revenue of $11.01 billion, up 6% year-over-year, with GAAP earnings per share rising 11% to $4.43. Adjusted EPS reached $5.44, reflecting continued operational strength and execution of its growth strategy.

The company highlighted new product launches and strategic collaborations, including a partnership with NVIDIA to integrate AI into scientific instruments. Thermo Fisher also completed the acquisition of Clario, repurchased $3 billion in shares, and increased its dividend by 10%.

Management indicated confidence in continued growth, supported by innovation, strong customer demand, and ongoing investments in capabilities and productivity.

Source: Business Wire

💬

Global Finance News 04-24-26

Thermo Fisher Partners with Singapore Biobank to Advance Proteomics Research

Thermo Fisher Scientific announced a strategic collaboration with Precision Health Research Singapore to support the PRECISE-SG100K study, a major population-scale biobank initiative.

The partnership will deploy advanced proteomics technologies to analyze large-scale biological data, aiming to improve disease detection, patient stratification, and personalized healthcare. The study involves over 100,000 participants and is one of Southeast Asia’s largest health research programs.

Thermo Fisher will integrate multiple proteomic platforms to generate high-resolution data, enabling researchers to uncover disease mechanisms and identify biomarkers more efficiently.

The collaboration reflects growing global investment in biobanks and AI-driven analytics as tools to advance precision medicine and long-term population health outcomes.
Business Wire

💬

WS Investor 04-09-26

Thermo Fisher completes $8.9 billion acquisition of Clario

March 24, 2026 — Thermo Fisher Scientific has completed its $8.875 billion acquisition of Clario Holdings, strengthening its position in clinical research and data-driven drug development.

Clario, a provider of endpoint data solutions for clinical trials, will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment. The company’s platform supports digital data collection and analysis across all phases of clinical trials and has contributed to around 70% of recent FDA and EMA novel drug approvals.

Thermo Fisher expects the acquisition to deliver strong financial returns, including double-digit internal rates of return and approximately $175 million in synergies by year five. The deal is also projected to contribute $0.45 to adjusted earnings per share in the first year.

The company said the acquisition enhances its ability to accelerate innovation and improve decision-making for pharmaceutical and biotech customers.
Business Wire

💬

WS Investor 03-25-26

Thermo Fisher Scientific reported solid fourth-quarter and full-year 2025 results, highlighting steady growth, strong execution, and active capital deployment.

In the fourth quarter, revenue rose 7% year over year to $12.21 billion, while GAAP diluted EPS increased 9% to $5.21 and adjusted EPS climbed 8% to $6.57. Operating performance remained robust, with GAAP operating margin improving to 18.5%. For the full year, revenue grew 4% to $44.56 billion, GAAP diluted EPS increased 7% to $17.74, and adjusted EPS rose 5% to $22.87.

The company underscored progress in its long-term growth strategy through major product launches across mass spectrometry, cryo-electron microscopy, lab automation, and bioprocessing, alongside regulatory approvals in diagnostics. Thermo Fisher also strengthened its strategic position through partnerships, including a collaboration with OpenAI to expand AI use across operations and products.

Capital deployment was a key theme in 2025, with approximately $16.5 billion deployed, including $13 billion in acquisitions and $3.6 billion returned to shareholders via buybacks and dividends. Management said the company enters 2026 from a position of strength, supported by its growth strategy, operational discipline, and expanding capabilities across biopharma, diagnostics, and scientific research.

💬

WS Investor 01-29-26

Thermo Fisher Scientific (NYSE: TMO) announced that its finance subsidiary, Thermo Fisher Scientific (Finance I) B.V., has completed a €2.1 billion notes offering. The issuance includes €1.0 billion in Floating Rate Senior Notes due 2027 and €1.1 billion in 3.628% Senior Notes due 2035, both fully guaranteed by Thermo Fisher on a senior unsecured basis.

The debt was issued under the company’s existing indenture structure and sold through an underwriting syndicate led by Barclays, BNP Paribas, HSBC Continental Europe and Morgan Stanley. Thermo Fisher expects net proceeds of approximately €2.09 billion, which will be used for general corporate purposes, including potential acquisitions, refinancing, working capital, capital expenditures or share repurchases.

💬

European Investor 12-02-25

Thermo Fisher Scientific announced that its EXENT System has received 510(k) clearance from the U.S. Food and Drug Administration, marking the first automated platform designed to aid in diagnosing multiple myeloma and related disorders.

The EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay provide high sensitivity and specific identification of M-proteins—abnormal antibodies produced by cancerous plasma cells—helping clinicians detect disease markers at very low concentrations. The system automates analysis to minimize subjective interpretation, accelerating and improving diagnostic accuracy for multiple myeloma, smoldering myeloma, Waldenström’s macroglobulinaemia, amyloidosis, and monoclonal gammopathy of undetermined significance.

Thermo Fisher stated that the EXENT System also improves laboratory workflow with up to six hours of walkaway time per shift and requires no mass spectrometry experience, broadening accessibility for clinical labs. Having already received Health Canada authorization, the system is now available for clinical use in 13 countries, including the U.S., U.K., Germany, France, and Australia.

Vice President Stephen Harding said the platform underscores Thermo Fisher’s mission to equip clinicians with tools that enhance diagnostic confidence and patient care through greater precision and efficiency.

💬

Global Finance News 11-12-25

Thermo Fisher Scientific to Acquire Clario for $8.9 Billion to Boost Digital Clinical Capabilities

Thermo Fisher Scientific (NYSE: TMO) announced an agreement to acquire Clario Holdings, Inc., a leader in digital endpoint data solutions for clinical trials, for $8.875 billion in cash, with up to $400 million in performance-based earn-outs. The acquisition enhances Thermo Fisher’s data and AI-driven offerings for pharmaceutical and biotech clients, helping accelerate drug development and improve clinical insights.

Clario, which has supported around 70% of FDA drug approvals over the past decade, is expected to generate $1.25 billion in 2025 revenue. The deal is projected to be immediately accretive, adding $0.45 to adjusted EPS in the first year post-closing, with about $175 million in operating synergies anticipated within five years. The transaction is expected to close by mid-2026, pending regulatory approvals, and Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment.

💬

The Investor 10-29-25

Thermo Fisher Scientific Inc. (NYSE: TMO) reported third-quarter 2025 revenue of $11.12 billion, a 5% increase year-on-year, with organic growth of 3%. GAAP diluted EPS was $4.27, roughly flat from a year earlier, while adjusted EPS rose 10% to $5.79.

GAAP operating income grew to $1.94 billion (up from $1.84 billion), and adjusted operating income reached $2.59 billion, yielding an adjusted operating margin of 23.3%, up 100 basis points year-over-year.

The company highlighted strong execution under its PPI Business System, continued innovation with new product launches such as the Oncomine Dx Express Test (FDA-approved for use with Dizal’s ZEGFROVY® in non-small cell lung cancer), and expanded research tools including the Olink Target 48 Neurodegeneration panel and the Talos 12 electron microscope.

Thermo Fisher also deepened its collaboration with OpenAI to accelerate the integration of artificial intelligence across operations and product development. Capital deployment included the acquisition of Solventum’s Filtration and Separation business and Sanofi’s Ridgefield, NJ sterile fill-finish site, along with $1.0 billion in share repurchases.

CEO Marc N. Casper said the results reflect “excellent operational performance” and reaffirmed confidence in achieving 2025 objectives while continuing to drive long-term value creation.

💬

European Investor 10-22-25

NYSE:TMOFollow

NYSE:TMO